PHILADELPHIA — The NFL offseason rarely slows long enough for one shock to settle before another begins forming. Just hours after the Baltimore Ravens abruptly backed out of their blockbuster trade for Maxx Crosby, the Philadelphia Eagles reportedly began assembling a calculated offer of their own.

Baltimore’s sudden withdrawal sent ripples across the league. What had been expected to become one of the defining transactions of the 2026 offseason collapsed under the weight of medical uncertainty.

Only days earlier, the Ravens and Las Vegas Raiders had reached a preliminary agreement. Baltimore would acquire Crosby — a five-time Pro Bowl edge rusher and one of the most relentless defenders in football — in exchange for two first-round draft picks.

Report: Maxx Crosby reportedly “couldn’t touch his toes” at the Physical today.

Not good. pic.twitter.com/TvnASvOlWR

— Adam Ferrell (@AdamFerrellNFL) March 11, 2026

One of those picks was believed to be Baltimore’s 2026 first-round selection, No. 14 overall, with another first-rounder scheduled for 2027. Crosby had already traveled to Baltimore as the deal approached completion.

But the final hurdle changed everything.

During his physical examination, concerns surfaced about Crosby’s knee — specifically lingering effects from a meniscus injury that required surgery last season. After reviewing the risk, the Ravens ultimately chose to cancel the trade.

Maxx Crosby did not pass his physical and is headed back to the Raiders, per @DMRussini

Ravens get their 2026 and 2027 first-round picks back 😳 pic.twitter.com/KzhmYWHLQA

— Bleacher Report (@BleacherReport) March 11, 2026

The Raiders confirmed the decision in a brief statement: “The Baltimore Ravens have backed out of our trade agreement for Maxx Crosby. We'll have no further comment at this time.”

Across the NFL, the failed blockbuster quickly became one of the most dramatic developments of the 2026 offseason.

Multiple reports from ESPN, NFL.com, and The Athletic indicated Baltimore’s decision was driven entirely by medical concerns rather than disagreements over compensation.

That unexpected opening quickly drew attention from several contenders — including Philadelphia.

According to league sources, the Eagles have explored a more conservative trade package that reflects the uncertainty surrounding Crosby’s health. Their proposal reportedly includes the No. 23 overall pick in the 2026 draft, a 2026 compensatory third-round pick (No. 98), and a young defensive lineman such as Moro Ojomo or Gabe Hall.

Following the Ravens’ decision to back out of the trade for Maxx Crosby due to concerns over his knee, his agent, CJ LaBoy, issued a statement clarifying that his client is ahead of schedule in his rehab and on track to be cleared for the offseason program. pic.twitter.com/v4auCGEAmM

— Football Forever (@fballforeverhq) March 11, 2026

Ojomo, 24, has shown flashes as a rotational interior defender with strong upside, while Hall is viewed internally as a young developmental lineman capable of growing into a larger role.

For Las Vegas, the structure offers flexibility if concerns about Crosby’s knee force the Raiders to reconsider the value of the market. Rather than waiting through prolonged uncertainty, they would receive a first-round pick along with young defensive talent and additional draft capital.

For Philadelphia, however, the strategy is clear.

Crosby’s relentless motor and elite production would immediately elevate the Eagles’ defensive front. His presence could transform an already talented defensive line into one of the most disruptive units in the NFC.

Just as importantly, the Eagles would avoid sacrificing multiple premium picks, preserving long-term roster depth while still acquiring one of the league’s most dominant pass rushers.

In a conference filled with elite quarterbacks and explosive offenses, consistent pressure remains one of the most valuable defensive advantages.

For now, Crosby technically remains a Raider.

But in the chaotic hours following Baltimore’s stunning reversal, Philadelphia has quietly positioned itself among the teams ready to capitalize if Las Vegas decides the market — even with medical concerns — is still worth exploring.